The costs associated with a drug’s clinical trials are so significant that it has become necessary to validate both its safety and efficacy in animal models prior to the continued study of the drug in humans.
Featuring contributions from distinguished researchers in the field of cognitive therapy research, Animal Models of Cognitive Impairment examines some of the most popular and successful animal archetypes used in the context of drug discovery. It provides integrated coverage of the latest research concerning neuronal systems relevant to cognitive function and dysfunction, assimilating reviews of this research within the context of each chapter. This approach is unique in that it brings together molecular and neurochemical methodologies, behavioral applications in translational models, and clinical applications.
The book comprehensively discusses a wide variety of animal models of cognitive impairment, including genetic, lesion, pharmacological, and aging related impairments. It also explores the significance of this research in regards to the treatment of various addictions and disorders such as stroke, autism, Alzheimer’s, schizophrenia, and ADHD.
Edited by two renowned authorities in the field, Animal Models of Cognitive Impairment is a timely book that provides integrated coverage of cutting-edge research that concerns neuronal systems relevant to cognitive function and dysfunction.
“This book has summarized the widely used animal models of cognitive impairment. The majority of the animal models are related to cognitive pharmacology. … The animals models of cognitive impairment described in this book are diverse and involve common cognitive diseases such as AD and schizophrenia. A general coverage of the broad aspects of cognitive impairment is realized. Besides the discussion of different animals for different cognitive syndromes, molecular, chemical and other approaches have been incorporated. All illustrated models were introduced by a short historical introduction and were critically discussed in the context of relevant literature. Each chapter ended with outlining the current state of the field and a short conclusion/summary. …”
— Rinske Vlamings, Department of Neuroscience, Maastricht University, The Netherlands, Yasin Temel, Department of Neurosurgery, University Hospital Maastricht, The Netherlands, in the Journal of Chemical Neuroanatomy, Vol. 33, No. 4, February 2007
Introduction; Edward D. Levin and Jerry I Buccafusco
Muscarinic Receptor Antagonists in Rats; Alvin V Terry, Jr.
Nicotinic Receptor Antagonists in Rats; Cindy S. Roegge and Edward D. Levin
Involvement of the NMDA System in Learning and Memory; Amir H. Rezvani
Animal Models and the Cognitive Effects of Ethanol; Merle G. Paule
Animal Models of Cognitive Impairment Produced by Developmental Lead Exposure; Deborah C. Rice
Developmental Behavioral Toxicity of Methylmercury: Consequences, Conditioning, and Cortex; M. Christopher Newland, Wendy D. Donlin, Elliott M. Paletz, and Kelly M. Banna
Executive Function following Developmental Exposure to Polychlorinated Biphenyls (PCBs): What Animal Models Have Told Us; Helen J.K. Sable and Susan L. Schantz
Modeling Cognitive Deficits Associated with Parkinsonism in the Chronic-Low-Dose MPTP-Treated Monkey; J.S. Schneider
Mouse Genetic Models
Cognitive Jmpairment in Transgenic Mouse Models of Amyloid Deposition; Dave Morgan
Cholinergic Receptor Knockout Mice; Lu Zhang
Assessments of Cognitive Deficits in Mutant Mice; Ramona Marie Rodriguiz and William C. Weisel
Model Applications and Future Developments
Cognitive Pharmacology in Aging Macaques; Jerry J. Buccaflisco
Cognitive Impairment following Traumatic Brain Injury; Mark D. Whiting, Anna I. Baranova, and Robert J. Jdamm
Cognitive Impairment Models Using Complementary Species; Daniel T. Cerutti and Edward D. Levin
Cognition Models and Drug Discovery; Michael W Decker